

Other version: https://smw.ch/article/doi/smw.2020.20446
![]() |
Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs |
|
Authors | ![]() | |
Published in | Swiss Medical Weekly. 2020, vol. 150, w20446 | |
Abstract | Hydroxychloroquine and lopinavir/ritonavir have been used as experimental therapies to treat COVID-19 during the first wave of the pandemic. Randomised controlled trials have recently shown that there are no meaningful benefits of these two therapies in hospitalised patients. Uncertainty remains regarding the potential harmful impact of these therapies as very early treatments and their burden to the health care system. The present study investigated the length of hospital stay (LOS), mortality, and costs of hydroxychloroquine, lopinavir/ritonavir or their combination in comparison with standard of care among patients hospitalised for coronavirus disease 2019 (COVID-19). | |
Keywords | Adolescent — Adult — Age Factors — Aged — Aged, 80 and over — Antiviral Agents/administration & dosage/adverse effects/therapeutic use — COVID-19/drug therapy/epidemiology/mortality — Child — Child, Preschool — Comorbidity — Drug Combinations — Drug Therapy, Combination — Health Expenditures — Hospital Mortality/trends — Humans — Hydroxychloroquine/administration & dosage/adverse effects/therapeutic use — Infant — Length of Stay/statistics & numerical data — Lopinavir/administration & dosage/adverse effects/therapeutic use — Middle Aged — Pandemics — Retrospective Studies — Ritonavir/administration & dosage/adverse effects/therapeutic use — SARS-CoV-2 — Severity of Illness Index — Sex Factors — Socioeconomic Factors — Therapies, Investigational/methods — Young Adult | |
Identifiers | PMID: 33382449 | |
Full text |
![]() ![]() Other version: https://smw.ch/article/doi/smw.2020.20446 |
|
Structures |
Faculté de médecine / Section de médecine clinique / Département d'anesthésiologie, pharmacologie, soins intensifs et urgences |
|
Research groups | Epidémiologie clinique et biostatistique (115) Groupe Desmeules Jules (pharmacologie/toxicologie) (567) Pharmaco-omiques et médecine de précision (1003) VIH/SIDA (930) Groupe Perrier Arnaud (Médecine interne générale, de réhabilitation et de gériatrie) (585) | |
Citation (ISO format) | VERNAZ-HEGI, Nathalie et al. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs. In: Swiss Medical Weekly, 2020, vol. 150, p. w20446. doi: 10.4414/smw.2020.20446 https://archive-ouverte.unige.ch/unige:151585 |